Cesar A. Perez

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.

Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.

Modified bi‐weekly cetuximab‐cisplatin and <scp>5‐FU</scp>/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients

Ethical surgical triage of patients with head and neck cancer during the <scp>COVID</scp>‐19 pandemic

Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma

Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas

Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation

Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

Poly(A) binding protein abundance regulates eukaryotic translation initiation factor 4F assembly in human cytomegalovirus-infected cells

Targeting the Met pathway in lung cancer

Primary Mediastinal Large B-Cell Lymphoma during Pregnancy